Cannabinoids in the management of spasticity associated with multiple sclerosis

Review

(2369) Views  (434) Full article downloads

Authors: Anna Maria Malfitano, Maria Chiara Proto, Maurizio Bifulco

Published Date August 2008 Volume 2008:4(5) Pages 847 - 853

DOI: http://dx.doi.org/10.2147/NDT.S3208

Anna Maria Malfitano, Maria Chiara Proto, Maurizio Bifulco

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Salerno

Abstract: The endocannabinoid system and cannabinoid-based treatments have been involved in a wide number of diseases. In particular, several studies suggest that cannabinoids and endocannabinoids may have a key role in the pathogenesis and therapy of multiple sclerosis (MS). In this study we highlight the main findings reported in literature about the relevance of cannabinoid drugs in the management and treatment of MS. An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of MS, including spasticity and pain. In this report we focus on the effects of cannabinoids in the relief of spasticity describing the main findings in vivo, in the mouse experimental allergic encephalomyelitis model of MS. We report on the current treatments used to control MS symptoms and the most recent clinical studies based on cannabinoid treatments, although long-term studies are required to establish whether cannabinoids may have a role beyond symptom amelioration in MS.

Keywords: cannabinoids, multiple sclerosis, spasticity